Topics
Gliomas | Treatment | Immunotherapy | Viruses
Home > Publications > Topics > Gliomas > Treatment > Immunotherapy > Viruses
*Rossmeisl JH, King JN, Robertson JL, Weger-Lucarelli J,
Elankumaran S.
Phase I/II Trial of
Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle
Disease Virus for Canine Intracranial Tumors.
Cancers
(Basel). 2024 Jan 29;16(3):564. doi:
10.3390/cancers16030564. PMID:
38339315. Interventional animal study. ˍ
Iqbal J, Hafeez MH, Amin A, Moradi I, Chhabra A, Iqbal A, Patel T,
Shafique MA, Nadeem A, Jamil U.
Synergistic
effects of herpes oncolytic virus and cyclophosphamide for
recurrent malignant glioma: a narrative review.
Ann
Med Surg (Lond). 2024 Jul 17;86(9):5354-5360. doi:
10.1097/MS9.0000000000002384. PMID:
39239066. Review. ˍ
Liu S, Liang R.
Oncolytic Virotherapy
for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical
and Research Strategies.
J
Multidiscip Healthc. 2025 Sep 26;18:6167-6185. doi:
10.2147/JMDH.S557248. PMID:
41040426. Bibliometric analysis. ˍ
Zeng W, Wang P, Fang S, Ge S, Jia W, Peng S, Wang M, Qin X, Zhang
W, Gao J, Su X, Yuan G, Wu J, Liu Y, Wang Y, Lu H, Mu R, Wu F,
Chang Q, Jin G, Meng F, Zhang J, Liu F.
ON-01,
an engineered recombinant oncolytic herpes simplex virus type-1,
in recurrent glioma: a single-arm, phase 1/2 study.
Neuro
Oncol. 2026 Jan 12:noag005. doi:
10.1093/neuonc/noag005. PMID:
41527280.
Trial
registration ID:
ChiCTR1900022570. ˍ